title: IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.
abstract: To function optimally as vaccines, dendritic cells (DCs) must actively migrate to lymphoid organs and maintain a viable, mature state for sufficient time to effectively present their Ag to cognate T cells. Unfortunately, mature DCs rapidly lose viability and function after injection, and only a minority leaves the vaccine site and migrates to lymph nodes. We show that all of these functions can be enhanced in DCs by removal of IL-1R-associated kinase M (IRAK-M). We found that IRAK-M is induced in DCs by TLR ligation and that its absence from these cells leads to increased activation of the p38-MAPK and NF-κB pathways, which, in turn, improves DC migration to lymph nodes, increases their longevity, and augments their secretion of Th1-skewing cytokines and chemokines. These biological effects have immunological consequences. IRAK-M(-/-) DCs increase the proliferation and activation of Ag-specific T cells, and a single vaccination with Ag-pulsed, LPS-matured IRAK-M(-/-) DCs eliminates established tumors and prolongs the survival of EG7 or B16.f10 tumor-bearing mice, without discernible induction of autoimmune disease. Thus, manipulation of IRAK-M levels can increase the potency of DC vaccines by enhancing their Ag-presenting function, migration, and longevity.
authors.affiliation: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: Meghan E
authors.initials: ME
authors.lastname: Turnis
authors.forename: Xiao-Tong
authors.initials: XT
authors.lastname: Song
authors.forename: Adham
authors.initials: A
authors.lastname: Bear
authors.forename: Aaron E
authors.initials: AE
authors.lastname: Foster
authors.forename: Stephen
authors.initials: S
authors.lastname: Gottschalk
authors.forename: Malcolm K
authors.initials: MK
authors.lastname: Brenner
authors.forename: Si-Yi
authors.initials: SY
authors.lastname: Chen
authors.forename: Cliona M
authors.initials: CM
authors.lastname: Rooney
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D015153:Blotting, Western; D019496:Cancer Vaccines / Q000276:immunology* / Q000378:metabolism; D049109:Cell Proliferation; D002469:Cell Separation; D002470:Cell Survival / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000276:immunology*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D053592:Interleukin-1 Receptor-Associated Kinases / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
chemical_list: D019496:Cancer Vaccines; C507771:IRAK3 protein, human; D053592:Interleukin-1 Receptor-Associated Kinases
references.citation: J Immunol. 2009 May 1;182(9):5217-24
references.pmid: 19380767
references.citation: J Hepatol. 2006 Aug;45(2):280-9
references.pmid: 16635535
references.citation: J Clin Invest. 2006 Jan;116(1):90-100
references.pmid: 16357940
references.citation: Clin Cancer Res. 2009 Apr 1;15(7):2531-40
references.pmid: 19318472
references.citation: J Immunol. 2005 Jul 15;175(2):959-66
references.pmid: 16002695
references.citation: Annu Rev Immunol. 2005;23:975-1028
references.pmid: 15771591
references.citation: Cell. 1999 Sep 3;98(5):609-16
references.pmid: 10490100
references.citation: J Biol Chem. 1999 Jul 2;274(27):19403-10
references.pmid: 10383454
references.citation: J Immunol. 2003 Nov 15;171(10):4984-9
references.pmid: 14607893
references.citation: Blood. 2003 Oct 1;102(7):2338-44
references.pmid: 12714511
references.citation: Nat Rev Immunol. 2003 Feb;3(2):133-46
references.pmid: 12563297
references.citation: J Exp Med. 2005 Apr 4;201(7):1169-77
references.pmid: 15809356
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: Blood. 2002 Mar 1;99(5):1517-26
references.pmid: 11861263
references.citation: Nature. 1998 Mar 19;392(6673):245-52
references.pmid: 9521319
references.citation: Springer Semin Immunopathol. 2005 Jan;26(3):329-41
references.pmid: 15609005
references.citation: J Immunother. 2008 Apr;31(3):294-309
references.pmid: 18317358
references.citation: Cell. 1999 Oct 1;99(1):23-33
references.pmid: 10520991
references.citation: Cancer Res. 2003 Jan 1;63(1):12-7
references.pmid: 12517769
references.citation: Cancer Res. 2003 Oct 1;63(19):6378-86
references.pmid: 14559827
references.citation: J Immunol. 2008 May 15;180(10):6941-6
references.pmid: 18453615
references.citation: Immunology. 2007 Aug;121(4):533-44
references.pmid: 17428311
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3825-30
references.pmid: 17606713
references.citation: Immunity. 2006 Jul;25(1):153-62
references.pmid: 16860764
references.citation: Immunity. 2002 Feb;16(2):257-70
references.pmid: 11869686
references.citation: J Exp Med. 2003 Aug 18;198(4):615-21
references.pmid: 12925677
references.citation: Nat Immunol. 2004 Jun;5(6):583-9
references.pmid: 15133508
references.citation: Crit Care Med. 2009 Feb;37(2):569-76
references.pmid: 19114913
references.citation: Cancer Immunol Immunother. 2009 Aug;58(8):1329-36
references.pmid: 19156413
references.citation: Cell. 2002 Jul 26;110(2):191-202
references.pmid: 12150927
references.citation: Springer Semin Immunopathol. 2005 Jan;26(3):273-87
references.pmid: 15338191
references.citation: Cancer Res. 2006 Jun 1;66(11):5910-8
references.pmid: 16740731
references.citation: Curr Opin Immunol. 2003 Apr;15(2):138-47
references.pmid: 12633662
references.citation: Haematologica. 2003 Oct;88(10):1139-49
references.pmid: 14555310
references.citation: Cancer Res. 2007 Nov 1;67(21):10528-37
references.pmid: 17974997
references.citation: Semin Immunol. 2003 Oct;15(5):271-6
references.pmid: 15001176
references.citation: J Clin Invest. 2006 Sep;116(9):2532-42
references.pmid: 16917541
references.citation: Eur J Immunol. 2002 Nov;32(11):3235-45
references.pmid: 12555669
references.citation: Nat Med. 2008 Mar;14(3):258-65
references.pmid: 18311150
references.citation: Immunity. 2008 Nov 14;29(5):795-806
references.pmid: 18951047
references.citation: APMIS. 2003 Jul-Aug;111(7-8):675-97
references.pmid: 12974772
references.citation: Mol Immunol. 2007 Apr;44(10):2558-65
references.pmid: 17267035
references.citation: Science. 2000 Sep 29;289(5488):2350-4
references.pmid: 11009421
references.citation: Nat Biotechnol. 2004 Dec;22(12):1546-53
references.pmid: 15558048
references.citation: J Immunol. 2003 Oct 15;171(8):4121-30
references.pmid: 14530334
references.citation: Nat Biotechnol. 2006 Dec;24(12):1581-90
references.pmid: 17143278
references.citation: Microcirculation. 2003 Jun;10(3-4):247-57
references.pmid: 12851642
references.citation: Immunity. 2005 Apr;22(4):493-505
references.pmid: 15845453
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5801-8
references.pmid: 17020987
references.citation: Int Rev Immunol. 2006 Sep-Dec;25(5-6):377-413
references.pmid: 17169781
references.citation: J Immunother. 2008 May;31(4):359-69
references.pmid: 18391760